Phase 2b Randomized Controlled Study of Tecemotide (L-BLP25) for Immunotherapy of NSCLC (Non-Small Cell Lung Cancer)
Clinical trial NCT00157209 · COMPLETED
Trial details
- NCT number
- NCT00157209
- Sponsor
- Merck KGaA, Darmstadt, Germany
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2000-08-01
- Primary completion
- 2006-03-01
- Enrollment
- 171
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.